How to buy Certara (CERT) stock

Certara, headquartered in Princeton, NJ, produces model-based pharmaceutical software.

Certara stock price (NASDAQ: CERT)

Use our graph to track the performance of CERT stocks over time.

Certara shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$26.31
52-week range	$23.00 - $41.79
50-day moving average	$26.54
200-day moving average	$30.01
Wall St. target price	$35.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Certara shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Certara stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Certara, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Certara price performance over time

Historical closes compared with the close of $26.31 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	-7.10%
3 months (2021-04-26)	-19.15%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Is Certara under- or over-valued?

Valuing Certara stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Certara's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Certara's EBITDA

Certara's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.6 million.

The EBITDA is a measure of a Certara's overall financial performance and is widely used to measure a its profitability.

To put Certara's EBITDA into context you can compare it against that of similar companies.

• Simulations Plus (SLP.US): USD$16.6 million
• Thermo Fisher Scientific (TMO.US): USD$12.4 billion

Certara financials

Revenue TTM	$252.8 million
Gross profit TTM	$142.8 million
Return on assets TTM	-1.18%
Return on equity TTM	-7.52%
Profit margin	-19.54%
Book value	$5.41
Market capitalisation	$3.9 billion

TTM: trailing 12 months

Shorting Certara shares

There are currently 1.8 million Certara shares held short by investors – that's known as Certara's "short interest". This figure is 14.2% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Certara shares can be evaluated.

Certara's "short interest ratio" (SIR)

Certara's "short interest ratio" (SIR) is the quantity of Certara shares currently shorted divided by the average quantity of Certara shares traded daily (recently around 538121.79104478). Certara's SIR currently stands at 3.35. In other words for every 100,000 Certara shares traded daily on the market, roughly 3350 shares are currently held short.

To gain some more context, you can compare Certara's short interest ratio against those of similar companies.

• Schrödinger (SDGR.US): 6.96
• Simulations Plus (SLP.US): 21.48
• Thermo Fisher Scientific (TMO.US): 1.45

However Certara's short interest can also be evaluated against the total number of Certara shares, or, against the total number of tradable Certara shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Certara's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Certara shares in existence, roughly 10 shares are currently held short) or 0.0297% of the tradable shares (for every 100,000 tradable Certara shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Certara.

Find out more about how you can short Certara stock.

Certara share dividends

We're not expecting Certara to pay a dividend over the next 12 months.

You may also wish to consider:

• Simulations Plus (SLP.US) (0.51% forward annual dividend yield)
• Thermo Fisher Scientific (TMO.US) (0.18% forward annual dividend yield)

Certara overview

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia.

Frequently asked questions

What percentage of Certara is owned by insiders or institutions?
Currently 6.611% of Certara shares are held by insiders and 78.767% by institutions. How many people work for Certara?
Latest data suggests 846 work at Certara. When does the fiscal year end for Certara?
Certara's fiscal year ends in December. Where is Certara based?
Certara's address is: 100 Overlook Center, Princeton, NJ, United States, 08540